Jürgen Behr

Maribavir in lung transplant recipients with cytomegalovirus infection: real-life experience

Abstract Introduction Cytomegalovirus remains a major challenge in LTx recipients. Despite advances in antiviral therapy, refractory and resistant CMV infections persist, and real-world data on maribavir, a recently approved UL97 kinase inhibitor, are limited. Methods We retrospe...